Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 6Neoplasms 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data 1Skin Neoplasms 1Neoplasm Metastasis 1Healthy Adults 1Glioblastoma 1Eye Neoplasms 1Esophageal Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Ipilimumab 17Nivolumab 15incomplete Freund's adjuvant 8Cyclophosphamide 7CTLA-4 Antigen 7pembrolizumab 6Ranibizumab 6sargramostim 5Radiosurgery 5Blood Specimen Collection 5tebentafusp 4Temozolomide 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4MART-1 Antigen 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4Bevacizumab 4fludarabine phosphate 3fludarabine 3aflibercept 3Thalidomide 3Sunitinib 3Specimen Handling 3MAGEA3 protein, human 3Interleukin-2 3130-nm albumin-bound paclitaxel 3relatlimab 2olaparib 2montanide ISA 51 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Uveal Melanoma × Peptides × Clear all
NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡